Maxim Group started coverage on shares of Soliton (NASDAQ:SOLY) in a research note released on Thursday morning, Briefing.com Automated Import reports. The brokerage issued a buy rating and a $22.00 price objective on the stock.

Separately, ValuEngine lowered shares of Soliton from a buy rating to a hold rating in a report on Tuesday, October 1st.

SOLY stock opened at $10.89 on Thursday. The firm’s 50-day moving average price is $11.49 and its two-hundred day moving average price is $12.70. Soliton has a 12-month low of $4.12 and a 12-month high of $29.00.

Several hedge funds have recently modified their holdings of SOLY. Tower Research Capital LLC TRC purchased a new position in shares of Soliton during the second quarter valued at approximately $32,000. California State Teachers Retirement System raised its holdings in shares of Soliton by 144.0% during the third quarter. California State Teachers Retirement System now owns 8,234 shares of the company’s stock valued at $88,000 after acquiring an additional 4,860 shares in the last quarter. Bank of Montreal Can purchased a new stake in Soliton in the second quarter worth $91,000. Royal Bank of Canada bought a new stake in Soliton in the second quarter valued at $96,000. Finally, Morgan Stanley purchased a new position in Soliton during the 2nd quarter valued at $121,000. Hedge funds and other institutional investors own 9.47% of the company’s stock.

Soliton Company Profile

Soliton, Inc, an early stage medical device company, focuses on developing and commercializing products using a proprietary rapid acoustic pulse technology platform. It offers a device for the removal of tattoos. The company was founded in 2012 and is headquartered in Houston, Texas.

See Also: What is the operating income formula?

Receive News & Ratings for Soliton Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soliton and related companies with MarketBeat.com's FREE daily email newsletter.